Antimicrobial resistance is a major societal problem as there are resistant bacteria to any antibiotic available, and they spread across countries and continents. For this a novel antibacterial medicine with a low potential of resistance development is urgently needed. Researchers from Spain, The Netherlands, and United Kingdom have joined efforts to identify bacterial histidine kinase inhibitors that can be further developed as novel antibacterial medicines.
An illustration from the paper, "Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients," published in Current Drug Targets. Courtesy of Dr. Nadya Velikova
Antimicrobial resistance is a major societal problem as there are resistant bacteria to any antibiotic available, and they spread across countries and continents. For this a novel antibacterial medicine with a low potential of resistance development is urgently needed. Researchers from Spain, The Netherlands, and United Kingdom have joined efforts to identify bacterial histidine kinase inhibitors that can be further developed as novel antibacterial medicines.
Cystic fibrosis (CF) is a genetic disorder in which the patients develop chronic bacterial infections caused mainly by Pseudomonas aeruginosa in the lungs, but there are also other pathogens involved in the lung disease typical for CF patients. All these pathogens rely on histidine kinases, as part of two-component systems to adapt to the diseased lung. In a recent publication in Current Drug Targets the potential to use bacterial histidine kinase inhibitors to treat bacterial infections in CF patients is studied by reviewing key TCS of different pathogens involved in CF lung disease.
The reviewed TCS are involved in the regulation of, among others, virulence, biofilm formation, and antibiotics resistance in pathogens common for lung disease in CF patients such as S. aureus, H. influenza, P. aeruginosa, and B. cepacia. Taken together with the presence of TCS in all major pathogens in CF and the conservation of the TCS domains, TCS inhibitors alone or in combination with currently used antibacterial treatment present an option for treating bacterial infections in CF patients worth exploring.
Reference: Velikova, N.; (2017). Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients. Current Drug Targets., DOI: 10.2174/1389450117666160208145934
Source: Bentham Science Publishers
Revolutionizing Infection Prevention: How Fewer Hand Hygiene Observations Can Boost Patient Safety
December 23rd 2024Discover how reducing hand hygiene observations from 200 to 50 per unit monthly can optimize infection preventionists' time, enhance safety culture, and improve patient outcomes.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
Announcing the 2024 Infection Control Today Educator of the Year: Shahbaz Salehi, MD, MPH, MSHIA
December 17th 2024Shahbaz Salehi, MD, MPH, MSHIA, is the Infection Control Today 2024 Educator of the Year. He is celebrated for his leadership, mentorship, and transformative contributions to infection prevention education and patient safety.
Pula General Hospital Celebrates Clean Hospitals
December 16th 2024Learn how Pula General Hospital in Croatia championed infection prevention and environmental hygiene and celebrated Clean Hospitals Day to honor cleaning staff and promote advanced practices for exceptional patient care and safety.